⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Attovia Therapeutics Appoints John W. Smither to Board of Directors
globenewswire.com
MBX
ARQT
NAMS
GNLX
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
globenewswire.com
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
globenewswire.com
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
globenewswire.com
ARQT
Form 8-K
sec.gov
ARQT
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
globenewswire.com
AMGN
BIIB
ISRG
UTHR
BKYI
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
globenewswire.com
ARQT
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
ARQT